Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)

American Journal of Kidney Diseases

Volumn 55, Issue 5, 2010, Pages 800-812

  Manns, Braden J ^a   Hodsman, Anthony ^b   Zimmerman, Deborah L ^c   Mendelssohn, David C ^d   Soroka, Steven D ^e,f,g   Chan, Chris ^h   Jindal, Kailash ⁱ   Klarenbach, Scott ⁱ  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

^f Nephrology Clinical Trials   (Canada)

^g Nova Scotia Provincial Dialysis Program   (Canada)

^h TORONTO GENERAL HOSPITAL   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; LANTHANUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALUMINUM OVERLOAD; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; BONE DENSITY; CALCIUM BLOOD LEVEL; CANADA; CHRONIC KIDNEY DISEASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; LABORATORY DIAGNOSIS; MEDICAL SOCIETY; METABOLIC BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; RENAL OSTEODYSTROPHY; VITAMIN D DEFICIENCY;

BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CANADA; DISEASE MANAGEMENT; FRACTURES, BONE; NUTRITIONAL STATUS; PARATHYROID HORMONE; PHOSPHORUS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 77951657694     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2010.02.339     Document Type: Article

References (34)

1. Manns B.J., White C.T., Madore F., et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int Suppl 110 (2008) S1-S3
2. National Kidney Foundation. IV. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 1 suppl 1 (2001) S182-S238
3. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S1-S146
4. McMahon L. The CARI guidelines. Biochemical and haematological targets. Haemoglobin. Nephrology (Carlton) 13 suppl 2 (2008) S44-S56
5. Locatelli F., Aljama P., Barany P., et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 suppl 2 (2004) ii1-ii47
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113 (2009) S1-S130
7. Rocco M.V., and Berns J.S. KDOQI in the era of global guidelines. Am J Kidney Dis 54 5 (2009) 781-787
8. Jindal K., Chan C.T., Deziel C., et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 17 3 suppl 1 (2006) S1-S27
9. Levin A., Hemmelgarn B., Culleton B., et al. Guidelines for the management of chronic kidney disease. CMAJ 179 11 (2008) 1154-1162
10. Manns B.J., Mendelssohn D.C., and Taub K.J. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ 7 2-3 (2007) 149-169
11. Klarenbach S.W. Economic evaluation in renal disease. J Nephrol 20 3 (2007) 251-259
12. Klarenbach S., and Manns B. Economic evaluation of dialysis therapies. Semin Nephrol 29 5 (2009) 524-532
13. Mendelssohn D.C. The evolution of nephrology guidelines: calling for a mid-course adjustment. Nephrol News Issues 23 9 (2009) 41-44
14. Phillips N., Barrett B., and Mendelssohn D.C. The role of physicians in political advocacy. Results of a Canadian Society of Nephrology survey. Nephrol News Issues 22 13 (2008) 6-7 32-33
15. Strippoli G.F., Craig J.C., and Schena F.P. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol 15 2 (2004) 411-419
16. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71 1 (2007) 31-38
17. Hemmelgarn B.R., Manns B.J., Zhang J., et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol 18 3 (2007) 993-999
18. Hemmelgarn B., Manns B., Lloyd A., et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 303 (2010) 423-429
19. Brown J.P., and Josse R.G. 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. CMAJ 167 10 suppl (2002) S1-S34
20. Kanis J.A., and WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4 (1994) 368-381
21. Siminoski K.G., Leslie W.D., and Frame H. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 56 (2007) 178-188
22. Toussaint N., Cooney P., and Kerr P.G. Review of dialysate calcium concentration in hemodialysis. Hemodial Int 10 4 (2006) 326-337
23. Al-Hejaili F., Kortas C., Leitch R., et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 14 9 (2003) 2322-2328
24. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 20 (2000) 1478-1483
25. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72 9 (2007) 1130-1137
26. Tonelli M., Wiebe N., Culleton B., et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 22 10 (2007) 2856-2866
27. Jamal S.A., Fitchett D., Lok C.E., Mendelssohn D.C., and Tsuyuki R.T. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 24 10 (2009) 3168-3174
28. Navaneethan S.D., Palmer S.C., Craig J.C., Elder G.J., and Strippoli G.F. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Am J Kidney Dis 54 4 (2009) 619-637
29. St. Peter W.L., Liu J., Weinhandl E., and Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51 3 (2008) 445-454
30. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 4 (2005) 1815-1824
31. Finn W.F. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 65 3 (2006) 191-202
32. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 21 (2009) 2019-2032
33. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42 4 suppl 3 (2003) S1-S201
34. Kestenbaum B., Andress D.L., Schwartz S.M., et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66 5 (2004) 2010-2016